[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
October 22, 1982

RBC Zinc Protoporphyrin to Screen Blood Donors for Iron Deficiency Anemia

Author Affiliations

From the Departments of Clinical Pathology (Drs Schifman and Finley) and Computer Systems and Biostatistics (Mr Thies), University of Arizona Health Sciences Center, and the Southern Arizona Red Cross Blood Center (Dr Rivers), Tucson. Presented in part at the 34th annual meeting of the American Association for Blood Banks, Chicago, Nov 4, 1981.

JAMA. 1982;248(16):2012-2015. doi:10.1001/jama.1982.03330160060025

We evaluated a rapid RBC zinc protoporphyrin (ZP) test in 1,147 male and 615 female blood donors to study its value in screening for evolving iron deficiency anemia. Fifteen men (1.8%) and 32 women (7.9%) who returned to donate were found to be anemic. A matched sample analysis between anemic and nonanemic donors demonstrated significant differences in serum ferritin levels, percent iron saturation, and the RBC ZP level from samples collected during the initial evaluation. Red cell ZP correlated well with the natural logarithm of serum ferritin in both men and women who later became anemic. The predictive value of RBC ZP levels compared favorably with that of the serum ferritin level. We also observed a strong association between the yearly donation frequency and RBC ZP concentration. These findings indicate that predonation RBC ZP testing may be useful in screening for iron depletion and potential risk of anemia in blood donors.

(JAMA 1982;248:2012-2015)